title: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
abstract: OBJECTIVE
  To determine the side effects and feasibility of cisplatin and carboplatin each in combination with paclitaxel as front-line therapy in advanced epithelial ovarian cancer.
  
  
  METHODS
  Patients were randomly allocated to receive paclitaxel 175 mg/m(2) intravenously as a 3-hour infusion followed by either cisplatin 75 mg/m(2) or carboplatin (area under the plasma concentration-time curve of 5), both on day 1. The schedule was repeated every 3 weeks for at least six cycles. Women allocated to paclitaxel-cisplatin were admitted to the hospital, whereas the carboplatin regimen was administered to outpatients.
  
  
  RESULTS
  A total of 208 eligible patients were randomized. Both regimens could be delivered in an optimal dose and without significant delay. Paclitaxel-carboplatin produced significantly less nausea and vomiting (P: <.01) and less peripheral neurotoxicity (P: =.04) but more granulocytopenia and thrombocytopenia (P: <.01). The overall response rate in 132 patients with measurable disease was 64% (84 of 132 patients), and in patients with elevated CA 125 levels at start, it was 74% (132 of 178 patients). With a median follow-up time of 37 months, the median progression-free survival time of all patients was 16 months and the median overall survival time was 31 months. The small number of patients entered onto the study caused wide confidence intervals (CIs) around the hazards ratio for progression-free survival of paclitaxel-carboplatin compared with paclitaxel-cisplatin (hazards ratio, 1.07; 95% CI, 0.78 to 1.48) and did not allow conclusions about efficacy.
  
  
  CONCLUSIONS
  Paclitaxel-carboplatin is a feasible regimen for outpatients with ovarian cancer and has a better toxicity profile than paclitaxel-cisplatin.
authors.affiliation: University Medical Center Utrecht, The Netherlands. j.p.neijt@digd.azu.nl
authors.forename: J P
authors.initials: JP
authors.lastname: Neijt
authors.forename: S A
authors.initials: SA
authors.lastname: Engelholm
authors.forename: M K
authors.initials: MK
authors.lastname: Tuxen
authors.forename: P G
authors.initials: PG
authors.lastname: Sorensen
authors.forename: M
authors.initials: M
authors.lastname: Hansen
authors.forename: C
authors.initials: C
authors.lastname: Sessa
authors.forename: C A
authors.initials: CA
authors.lastname: de Swart
authors.forename: F R
authors.initials: FR
authors.lastname: Hirsch
authors.forename: B
authors.initials: B
authors.lastname: Lund
authors.forename: H C
authors.initials: HC
authors.lastname: van Houwelingen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004848:Epithelium / Q000473:pathology; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D016019:Survival Analysis; D043823:Taxoids
chemical_list: D043823:Taxoids; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin